Relapsed cervicomediastinal lymph node carcinoma with an unknown primary site treated with TS-1 alone: a case report

BMC Research Notes

Hiroyuki Kuwano¹  Shigebumi Tanaka¹  Akira Mogi¹  Yoshinori Shitara¹  Ryoichi Onozato¹  Toshiki Yajima¹ 

[1] Department of General Surgical Science (Surgery I), Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, 371-8511, Maebashi-shi, Gunma, Japan

关键词: Chemotherapy;    TS-1;    Carcinoma with an unknown primary site;    Mediastinal lymph node;   

Others  :  1135081
DOI  :  10.1186/1756-0500-6-558

 received in 2013-03-20, accepted in 2013-12-20,  发布年份 2013

【 摘 要 】

Background

Cervicomediastinal lymph node carcinoma with an unknown primary site is quite rare, and useful treatment of these diseases has not been established. We report here the case of a patient successfully treated with TS-1 alone after the relapse of cervicomediastinal lymph node carcinoma with an unknown primary site.

Case presentation

A 62-year-old man was referred to our hospital because of cervicomediastinal lymph node swelling and high serum levels of carbohydrate antigen 19-9 and carcinoembryonic antigen. Fluorodeoxyglucose-positron emission tomography/computed tomography revealed an accumulation of fluorodeoxyglucose in the left supraclavicular lymph nodes, mediastinal lymph nodes, and the pelvic cavity. Colonoscopy revealed rectal cancer, which was diagnosed by biopsy as a tubular adenocarcinoma. Because metastases from rectal cancer to the cervicomediastinal lymph nodes are rare, the patient underwent thoracoscopic mediastinal lymphadenectomy. A biopsy specimen from the paraaortic lymph nodes demonstrated papillary adenocarcinoma that was pathologically different from the rectal cancer; therefore, a diagnosis of mediastinal carcinoma with an unknown primary site was established. The patient underwent low anterior resection of the rectum for the rectal cancer, and no abdominal lymph node metastasis (pMP, N0/stage I) was found. Although radiotherapy was performed for the cervicomediastinal lymph nodes, the mediastinal carcinoma relapsed after 6 months. Because the patient desired oral chemotherapy on an outpatient basis, TS-1 was administered at a dosage of 80 mg/day for 2 weeks, followed by a 1-week rest. TS-1 treatment resulted in a decrease in the size of the cervicomediastinal lymph nodes, and the serum tumor marker levels decreased to normal after the fourth course. The patient continued TS-1 treatment without adverse events and is currently alive without recurrence or identification of the primary site at the 32nd month after TS-1 treatment.

Conclusion

This is the first reported case of relapsed cervicomediastinal lymph node carcinoma with an unknown primary site treated by TS-1 alone. TS-1 treatment for the carcinoma with an unknown primary site may be useful in patients who are not candidates for systemic platinum-based chemotherapy.

【 授权许可】

   
2013 Yajima et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Pavlidis N, Pentheroudakis G: Cancer of unknown primary site. Lancet 2012, 379:1428-1435.
• [2]Holmes FF, Fouts TL: Metastatic cancer of unknown primary site. Cancer 1970, 26:816-820.
• [3]Didolkar MS, Fanous N, Elias EG, Moore RH: Metastatic carcinomas from occult primary tumors. A study of 254 patients. Ann Surg 1977, 186:625-630.
• [4]Pavlidis N, Fizazi K: Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009, 69:271-278.
• [5]Riquet M, Badoual C, Le Pimped BF, Dujon A, Danel C: Metastatic thoracic lymph node carcinoma with unknown primary site. Ann Thorac Surg 2003, 75:244-249.
• [6]Miwa K, Fujioka S, Adachi Y, Haruki T, Taniguchi Y, Nakamura H: Mediastinal lymph node carcinoma of an unknown primary site: clinicopathological examination. Gen Thorac Cardiovasc Surg 2009, 57:239-243.
• [7]Nakano T, Endo S, Endo T, Hasegawa T, Nakayama M, Sugiyama Y, Hironaka M: Multimodal treatment for multistation mediastinal lymph node adenocarcinoma: a case report. Ann Thorac Cardiovasc Surg 2012, 18:136-139.
• [8]Tomita M, Matsuzaki Y, Shimizu T, Hara M, Ayabe T, Enomoto Y, Onitsuka T: Squamous cell carcinoma of the hilar lymph node with unknown primary tumor: a case report. Ann Thorac Cardiovasc Surg 2008, 14:242-245.
• [9]Miyoshi K, Okumura N, Kokado Y, Matsuoka T, Kameyama K, et al.: Metastatic thoracic lymph node carcinoma of unknown origin. Jpn J Lung Cancer 2007, 47:245-250. (in Japanese)
• [10]Lee J, Hahn S, Kim DW, Kim J, Kang SN, Rha SY, Lee KB, Kang JH, Park BJ: Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. Br J Cancer 2013, 108:39-48.
• [11]Shiota Y, Imai S, Sasaki N, Tahara K, Noma B, Horita N, Taniguchi A, Ono T: A case of mediastinal lymph node carcinoma of unknown primary site treated with docetaxel and cisplatin with concurrent thoracic radiation therapy. Acta Med Okayama 2011, 65:407-411.
• [12]Satoh T, Sakata Y: S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother 2012, 13:1943-1959.
• [13]Okamoto I, Fukuoka M: S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2009, 10:290-294.
• [14]Moller AK, Loft A, Berthelsen AK, Damgaard Pedersen K, Graff J, Christen CB, Perell K, Petersen BL, Daugaard G: 18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review. Oncologist 2011, 16:445-451.
• [15]Kawasaki K, Kamigaki T, Takase S, Maki K, Tamura T, Shirasaka D, Shinoda H, Nakamura T, Kuroda D, Kuroda Y: A case of unknown primary cancer responding to TS-1. Gan To Kagaku Ryoho 2006, 33:1125-1128. (in Japanese)